Key Highlights
- The third-quarter net loss was USD 6.85 million against USD 8.62 million a year earlier, while nine-month net loss fell to USD 31.53 million from USD 46.41 million.
- Cash and cash equivalents were USD 8.7 million on September 30, 2026, which management said funds operations only into early 2027, and the filing flags substantial doubt about continuing as a going concern.
- Stockholders will vote on the Avere Therapeutics Merger on December 9, 2026, after the registration statement was declared effective on November 6, 2026.
- Avere's private financing commitments total about USD 820.0 million, of which about USD 266.0 million will come from converting its notes rather than new cash.
Merger Costs Lift Expenses as Research Spending Winds Down
NextCure (NASDAQ:NXTC) filed its Quarterly Report on November 10, 2026 for the period ended September 30, 2026. It is a biopharmaceutical company that had focused on cancer therapies and is now mainly supporting collaboration obligations, managing legacy Assets and completing the merger. Research and Development expense fell to USD 4.54 million from USD 6.14 million. General and administrative expense rose to USD 4.43 million from USD 2.81 million, with USD 1.8 million of the increase tied to merger legal, accounting and other fees. A net restructuring and Impairment Credit of USD 2.04 million in the quarter eased the operating loss to USD 6.92 million from USD 8.95 million.
Avere Merger Terms, December 9 Vote and Dilution
The merger agreement was signed on July 14, 2026, and the combined company is expected to operate as Avere Therapeutics. Avere's financing includes a USD 320.0 million private financing and an added USD 500.0 million Placement priced at a higher valuation, which the filing says does not change the exchange ratio. The Record Date was November 3, 2026. Because new shares convert at that ratio, the extra financing further reduces the share of the combined company held by current NextCure holders, which the filing describes as substantial dilution. Current holders are also expected to receive contingent value rights covering 90% of net proceeds from sales or licenses of legacy assets, with no assurance anything will be paid.
SIM0505 Halted and LNCB74 Handed to LigaChem
The company stopped enrolling patients in its SIM0505 study in July 2026, moved all patients off study by August 31, withdrew the investigational application in October 2026 and is seeking partners for the drug. It said the decision was not based on negative safety or efficacy findings. Interim data presented in June showed a 55% objective response rate in evaluable gynecologic cancer patients in the therapeutic dose range. LigaChem took over sponsorship of the LNCB74 program on October 6, 2026, and owes NextCure milestones and single-digit royalties. Going-concern doubt matters because cash of USD 8.7 million is small against an accumulated Deficit of USD 468 million, so the merger and its financing carry the outlook.
Where Things Stand
It means very little runway without the merger. NextCure (NASDAQ:NXTC) cut research costs and narrowed its quarterly loss to USD 6.85 million, but USD 8.7 million of cash only reaches early 2027, and the filing says completing the Avere deal is central to its plan. Holders face heavy dilution in exchange for contingent value rights whose payout depends on selling legacy assets. The filing gives no price reaction. Next markers are the stockholder vote on December 9, 2026, merger closing and any sale or license of SIM0505.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...